Table 2.
PEGylated and lipidated peptide and protein drugs on the market, as stated by the FDA [11].
| compound | product name (company) |
indication | market entry (FDA approval) |
| PEGademase bovine | Adagen® (sigma-tau) |
severe combined immunodeficiency disease | 1990 |
| PEGaspargase | Oncaspar® (sigma-tau) |
acute lymphoblastic leukemia | 1994 |
| PEGinterferon α-2b | PEGIntron® (Merck) |
hepatitis C; also in combination with ribavirin | 2001 |
| PEGinterferon α-2b | Sylatron® (Merck) |
malignant melanoma | 2001 |
| PEGfilgrastim | Neulasta® (Amgen) |
neutropenia during chemotherapy | 2002 |
| PEGinterferon α-2a | Pegasys® (Hoffmann-La Roche) |
hepatitis C; also in combination with ribavirin | 2002 |
| PEGvisomant | Somavert® (Pfizer) |
acromegaly | 2003 |
| PEGaptanib | Macugen® (Pfizer) |
wet age-related macular degeneration | 2004 |
| mPEG-epoetin β | Mircera® (Hoffmann-La Roche) |
symptomatic anaemia associated with chronic kidney disease | 2007 |
| Certolizumab PEGol | Cimzia® (UCB) |
rheumatoid arthritis and Crohn's disease | 2008 |
| PEGloticase | Krystexxa® (Savient Pharmaceuticals) |
refractory chronic gout | 2010 |
| Insulin detemir | Levemir® (Novo Nordisk) |
diabetes mellitus | 2005 |
| Liraglutide | Victoza® (Novo Nordisk) |
diabetes mellitus type 2 | 2010 |